Skip to content
Menu

Novo Nordisk A/S NVO

Full chart Compare
Set alert

Price alert · NVO

All alert types
41.60 USD -0.03 (-0.07%)

Regular-session close

41.54 -0.06 -0.14%

After hours · Nov 16, 7:33 PM ET

41.44 Day range 42.30
35.12 52-week range 64.16
YTD
-18.24%
1 year
-13.80%
Market cap
183.39B
Revenue (ttm)
333.65B
Profit margin
33.92%
EPS (ttm)
3.96
Shares out
3.33B
P/E ratio
10.51
Forward P/E
12.10
Dividend
1.80 (4.32%)
Ex-dividend date
Aug 17, 2026
YTD return
-18.24%
1-year return
-13.80%
Volume
15.99M
Avg volume
12.36M
Open
42.05
Previous close
41.63
Day's range
41.44 – 42.30
52-week range
35.12 – 64.16
Beta
0.37
Analysts
Hold
Price target
45.39 (+9.1%)
Earnings date
Feb 3, 2027
50-day average
40.09

5D +0.99 (+2.44%)

404142TueWedThuFriMon41.61

Key statistics

200-day average
43.18
Enterprise value
271.68B
PEG ratio
4.31
Price / sales
0.55
Price / book
5.60
Payout ratio
45.36%
Revenue growth
5.60%
Free cash flow
32.75B
Total cash
46.35B
Total debt
134.48B
Return on equity
58.38%
Short % of float
1.21%

Fundamental scorecard

21 of 25 checks passed on NVO’s reported financials

ValueGrowthProfitabilityHealthDividend

21of 25 checks passed

  • Value 5 of 5
  • Growth 4 of 5
  • Profitability 4 of 5
  • Financial health 3 of 5
  • Dividend 5 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
NVO Revenue — quarterly 79.19B
NVO Net income — quarterly 16.74B
NVO EPS — quarterly 3.80

Earnings

NVO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 3, 2027Dec 30, 20260.68———
Nov 4, 2026Sep 30, 20260.7310.89+0.16+21.75%
Aug 5, 2026Jun 30, 20260.820.96+0.14+17.07%
May 6, 2026Mar 31, 20260.871.04+0.17+19.54%
Feb 3, 2026Dec 31, 20250.901.00+0.10+11.11%
Nov 5, 2025Sep 30, 20250.771.02+0.25+32.47%

Upgrades / downgrades

NVO analyst upgrades and downgrades
DateFirmActionFromTo
Oct 12, 2026BMO CapitalmainMarket PerformMarket Perform
Sep 11, 2026Morgan StanleydownEqual-WeightUnderweight
Mar 2, 2026Goldman SachsdownBuyNeutral
Feb 24, 2026JP MorgandownOverweightNeutral
Jan 9, 2026CICCinit—Outperform
Dec 8, 2025Argus ResearchdownBuyHold

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
Denmark

News

Your note

Sign in to keep a note on NVO — it syncs with the Stock Master app.

Institution ownership

NVO institution ownership
Holder% heldSharesValueReported
Dodge & Cox Inc.0.60%20,352,460846.66MSep 29, 2026
LOOMIS SAYLES & CO L P0.53%17,851,108742.61MSep 29, 2026
Arrowstreet Capital, Limited Partnership0.50%17,093,966711.11MSep 29, 2026
Franklin Templeton, Inc.0.40%13,472,490560.46MSep 29, 2026
Morgan Stanley0.38%13,006,793541.08MSep 29, 2026
Price (T.Rowe) Associates Inc0.35%11,704,719486.92MJun 29, 2026

Fund ownership

NVO fund ownership
Holder% heldSharesValueReported
Dodge & Cox Funds-Dodge & Cox Stock Fund0.45%15,240,800634.02MJun 29, 2026
PUTNAM LARGE CAP VALUE FUND0.24%7,975,159331.77MJul 30, 2026
WASHINGTON MUTUAL INVESTORS FUND0.16%5,338,458222.08MSep 29, 2026
LOOMIS SAYLES FUNDS II-Loomis Sayles Growth Fund0.15%5,111,619212.64MJun 29, 2026
AMERICAN BALANCED FUND0.14%4,750,000197.60MSep 29, 2026
TR PRICE-Price (T.Rowe) International Growth Equity Trust0.10%3,454,365143.70MJun 29, 2026